PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis
Canadian Journal of Physiology and Pharmacology · 2024
DOI: 10.1139/cjpp-2023-0031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2024. Verfasst von Mohamed Zaza und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxic1ology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
This study concerned with assessing the effect of restoring p53 using PRIMA-1 on the anti-cancer activity of olaparib against TP53-mutant triple negative breast cancer (TNBC) cells and exploring the optimum synergistic concentrations and the underlying mechanism. Human BC cell lines, MDA-MB-231 with mutated TP53 gene, and MCF-7 with wild-type TP53 gene were treated with olaparib and/or PRIMA-1. The IC 50 value for olaparib was significantly decreased by PRIMA-1 in MDA-MB-231 cells compared to MCF-7 cells. Contrary to MCF-7 cells, co-treatment with olaparib and PRIMA-1 had a synergistic anti-proliferative effect in MDA-MB-231 at all tested concentrations with the best synergistic combination at 45 and 8.5 µM, respectively, and furthermore PRIMA-1 enhanced olaparib-induced apoptosis. This synergistic apoptotic effect was associated with a significant boost in mRNA expression of TP53 gene, cell cycle arrest at G2/M phase, modulation of BRCA-1, BAX and Bcl2 proteins expressions, and induction of active caspase-3. These results present a clue for the utility of combined olaparib and PRIMA-1 in treatment of TP53-mutant TNBC invitro. PRIMA-1 triggers olaparib-induced MDA-MB-231 cell death in a synergistic manner via restoring TP53, decreasing BRCA-1 expression, cell cycle arrest, and enhancement of apoptosis via p53/BAX/Bcl2/caspase 3 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxic1ology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
- Children's Cancer Hospital Egypt (CCHE 57357), Cairo, Egypt.
ORCID-Profile: Memy H Hassan
Zitieren
APA
Zaza, M., Rashed, M. H., Elrefaey, H., Hassan, M. H., Abo-Salem, O. M., & El-Sayed, E. S. M. (2024). PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2023-0031
Vancouver
Zaza M, Rashed MH, Elrefaey H, Hassan MH, Abo-Salem OM, El-Sayed ESM. PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis. Canadian Journal of Physiology and Pharmacology. 2024. doi:10.1139/cjpp-2023-0031
BibTeX
@article{Zaza2024,
author = {Zaza, Mohamed and Rashed, Mohammed H and Elrefaey, Hesham and Hassan, Memy H and Abo-Salem, Osama M and El-Sayed, El-Sayed M},
title = {PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2024},
doi = {10.1139/cjpp-2023-0031}
}
EUVIMED